ACUTE MYOCARDIAL INFARCTION WITH VITAMIN B12 DEFICIENCY AND MILD HYPERHOMOCYSTEINEMIA: A CASE REPORT AND REVIEW by Umarje, Siddhi et al.
Vol 9, Issue 6, 2016
Online - 2455-3891 
Print - 0974-2441
ACUTE MYOCARDIAL INFARCTION WITH VITAMIN B12 DEFICIENCY AND MILD 
HYPERHOMOCYSTEINEMIA: A CASE REPORT AND REVIEW
SIDDHI UMARJE1, PANDA BK1, MADHU BANSODE2
1Department of Clinical Pharmacy, Poona College of Pharmacy, Bharati Vidyapeeth University, Pune, Maharashtra - 411 046, India. 
2Department of Medicine, Bharati Medical College and Hospital, Bharati Vidyapeeth University, Pune, Maharashtra - 411 046, India. 
Email: bijoymaximus@gmail.com
Received: 02 July 2016, Revised and Accepted: 05 July 2016
ABSTRACT
A 38-year-old male was diagnosed with acute myocardial infarction (AMI) without a history of any significant clinical conditions. His subjective 
complaints and objective findings were clearly suggesting an acute ischemic attack along with vitamin B12 deficiency. While managing him for AMI, 
serology tests for vitamin B12 revealed low levels along with the mild elevation of serum homocysteine level. He was managed with thrombolytic 
agent, β-adrenergic blocker, aspirin, antiplatelet agents, anticoagulants, statin, vitamin B complex, and folic acid supplements. The clinical pharmacist 
intervened by suggesting discontinuation of clopidogrel as two antiplatelet agents (clopidogrel and ticagrelor) were administered along with an 
anticoagulant, thereby increasing the risk of bleeding in the patient. Clopidogrel was stopped as ticagrelor is a better antiplatelet agent when given 
in combination with low dose aspirin. Furthermore, aspirin dose was reduced to enhance the efficacy of ticagrelor and provide better secondary 
prevention for vascular diseases.
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Case Report
INTRODUCTION
Homocysteine (HCY) is an intermediate product formed during 
the intracellular metabolism of dietary methionine which 
requires folic acid, vitamin B12, and vitamin B6 for its catabolism. 
Deficiency of vitamin B12 can lead to saturation of HCY causing 
hyperhomocysteinemia [1]. This HCY has direct toxic effects on 
vascular vessel walls due to the generation of oxidative free radicals. 
Generation of such oxidative free radicals initiates atherogenesis. 
A chain of reactions takes place due to the oxidative free radicals 
causing endothelial injury which promotes atherosclerosis. Several 
studies have identified hyperhomocysteinemia as a risk factor for 
coronary artery syndromes [2-6].
Few case reports were published on hyperhomocysteinemia as a risk 
factor for coronary artery syndromes in young adult patients. We 
present a case of 38-year-old male diagnosed with acute myocardial 
infarction (AMI) subsequently with vitamin B12 deficiency and mild 
hyperhomocysteinemia. A comparative case report evaluation has 
been conducted to identify the differences and similarities in clinical 
presentation, laboratory investigation reports, and management.
CASE REPORT
A 38-year-old man with no significant medical history presented with 
complaints of chest pain, sweating, nausea, tingling in both the upper 
limbs, and backache. He was transferred from a primary health-care 
setting and was admitted to a tertiary care hospital. Electrocardiogram 
(ECG) done at the primary health-care setting provided an impression 
of ST-segment elevation suggestive of hyper-AMI. Another ECG done 
on admission to the tertiary care hospital revealed ST-segment 
elevation with lateral wall of left ventricle hypokinetic and moderate 
left ventricular systolic dysfunction. He was otherwise vitally stable, 
conscious, and oriented. The patient suffered from jaundice 3 years 
back and had a family history of ischemic heart disease but no other 
co-morbid conditions. The patient was a non-smoker and followed the 
Mediterranean diet.
Laboratory tests performed on admission revealed a platelet count of 
247,000/cmm; hemoglobin level 15.1 g/dL, borderline high red blood 
cells (RBC) indices, and RBC morphology were normal, thus showing no 
signs of anemia. Liver function tests were normal. Lipid profile revealed 
serum cholesterol 186 mg/dL and serum low-density lipoproteins 
cholesterol 129.8 mg/dL, which was considered to be normal. Cardiac 
enzymes were checked and were found to be highly elevated (troponin 
I 0.54 ng/ml [0-0.04 ng/ml], serum creatinine phosphokinase [CPK] 
457 IU/L [25-200 IU/L], and CPK-MB 38 IU/L [0-25 IU/L]) suggesting 
an ischemic attack.
Treatment was initiated with injection streptokinase 25,000 IU to 
thrombolysis and recanalize the occluded artery, and the patient was 
prescribed with on the tablet. Metoprolol 25 mg twice daily, tablet. 
Aspirin 150 mg once daily, tablet. Clopidogrel 75 mg twice daily, tablet. 
Atorvastatin 80 mg once daily at night, tablet. Nicorandil 5 mg twice 
daily along with injection. Ondansetron 4 mg thrice in a day and tablet. 
Alprazolam 0.5 mg once daily at night. Coronary angiography revealed 
recanalized left anterior descending coronary artery having a slow blood 
flow requiring medical management. Thus, on day 2, tablet. Ticagrelor 
(90 mg) twice daily and a low molecular weight heparin (injection 
enoxaparin 60 mg/0.6 ml) were added to improve the coronary artery 
blood flow. Chest pain, nausea, sweating, and backache were resolved 
completely by day 3, but the tingling sensation persisted. Thus, 
suspecting a vitamin B12 deficiency, the patient’s serum vitamin B12 
and HCY levels were checked which revealed vitamin B12 level as 89 pg/
ml (187-883 pg/ml) and serum HCY as 15.65 µmol/L (0-15 µmol/L). 
Hence, this confirmed vitamin B12 deficiency with mild elevation of 
HCY levels. The patient was immediately put on oral supplementation of 
vitamin B12 (1.5 mg) + vitamin B6 (20 mg) + folic acid (5 mg) once daily. 
He was discharged on day 5 and was continued on atorvastatin, nitrate, 
vitamin B complex, ticagrelor, and aspirin at a low dose (100 mg). He 
was asked to visit the hospital for a follow-up after 2 weeks.
We have conducted a search on AMI, vitamin B12 deficiency, and 
hyperhomocysteinemia. Pertinent case reports were searched 
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for in PubMed for “AMI” and “vitamin B12 deficiency,” or 
“hyperhomocysteinemia.” Articles were limited to case reports and 
English language. The search strategy was set until the end of April 
2016. The clinical reports showing patient diagnosed with AMI having 
vitamin B12 deficiency and hyperhomocysteinemia without any co-
morbid conditions such as diabetes, hypertension, hyperlipidemia, and 
obesity were compared for similarities and differences with our case.
Table 1 gives a brief comparison between our case and similar published case 
reports of AMI with vitamin B12 deficiency and hyperhomocysteinemia.
DISCUSSION
Hyperhomocysteinemia is defined as a medical condition characterized 
by an abnormally high level (>15 µmol/L) of HCY in blood. It is classified 
as moderate (16-30 µmol/L), intermediate (31-100 µmol/L), and 
severe (>100 µmol/L) hyperhomocysteinemia [11]. Elevated plasma 
HCY levels can be caused by a number of factors, including folate and 
vitamin B12 deficiency, pre-existing atherosclerotic disease, diabetes, 
and various drugs [12]. Mild elevation in HCY level is associated with the 
low levels of vitamin B12 and enhances the formation of atherosclerotic 
plaque. Thus, it is a risk factor for major vascular events. The threshold 
level for elevated values of plasma HCY in males is 11.4 µmol/L. Above 
this level, there is a risk of formation of atherosclerotic plaque [13,14]. 
Few epidemiological studies conducted in India has reported a high 
prevalence of elevated plasma HCY level in the study population [15,16].
Case 1 [7] and Case 2 [8] mentioned that the patient complained of 
paresthesia which was observed in our case too. The patients were [7,8] 
diagnosed with pernicious anemia suggesting the etiology behind 
vitamin B12 deficiency. Case 3 [9] and Case 4 [10] did not report any 
subjective complaints of vitamin B12 deficiency at the time of hospital 
admission irrespective of low serum vitamin B12 level. When Case 2 [8] 
was compared with our case, it was found that the serum vitamin B12 
level in the patient [8] was comparatively higher (158 pg/ml) but had 
severe hyperhomocysteinemia (serum HCY: 105 µmol/L). The striking 
difference was of the presence of pernicious anemia in the reported 
case [8]. Thus, it is difficult to establish a relationship between the severity 
of vitamin B12 deficiency and the degree of hyperhomocysteinemia 
(moderate/intermediate/severe). Furthermore, one of the significant 
differences between our case and all the published case reports [7-10] 
was the finding of hemoglobin level. The arithmetic mean of hemoglobin 
levels found in patients reported in all the case reports was found to be 
10.85 g/dL. This calculated mean hemoglobin level was comparatively 
lower than the hemoglobin level of our patient (15.1 g/dL).
As Case 1 [7] and Case 2 [8] patients were diagnosed with pernicious 
anemia, the deficiency of vitamin B12 was managed by parenteral 
(subcutaneous/intramuscular) vitamin B12 supplementation. Other 
published case reports [9,10] have not mentioned about the presence 
of pernicious anemia in the patient, and thus, it can be assumed that 
they were managed by oral vitamin B12 supplementation. Similarly, 
the vitamin B12 deficiency in our patient was managed by oral 
supplementation of vitamin B12, vitamin B6, and folic acid.
After conducting a literature review of the published case reports 
which were similar to our case, it was found that the information 
available from the published literature is not sufficient to understand 
the relationship between severity and cause of vitamin B12 deficiency 
and its effect on serum HCY level. One of the meta-analysis though 
supported an association between the elevated HCY levels and 
increased risk of cardiovascular disease (CVD) [16]. Even it is proposed 
that HCY levels can be considered as a marker rather than a risk factor 
as the impact of vitamin supplementation does not significantly reduce 
the risk of CVD. Furthermore, other factors such as folic acid and/or 
vitamin B6 (pyridoxine) deficiency, deficiency of enzymes required for 
HCY metabolism or other genetic factors, and diseases or drugs should 
be considered in patients with moderate vitamin B12 deficiency having 
severe hyperhomocysteinemia.
The highlight of this case was the clinical pharmacist’s intervention. On 
day 2, ticagrelor (antiplatelet agent) and a low molecular weight heparin 
(LMWH), i.e. enoxaparin (anticoagulant) were added to the regimen. The 
patient was already receiving an antiplatelet agent (clopidogrel 75 mg) in 
combination with aspirin (150 mg). This possibly could have increased the 
risk of bleeding in the patient. Hence, clopidogrel was advised to STOP as 
ticagrelor is a better antiplatelet agent. Furthermore, the dose of aspirin 
was reduced at the time of discharge of the patient because aspirin above 
100 mg decreases the efficacy of ticagrelor. It has been clearly mentioned 
in the Food and Drug Administration black box warning [17] and NICE 
guidelines [18] that aspirin should be given at a low dose (75-100 mg) 
when administered in combination with ticagrelor. Benefits of ticagrelor 
over clopidogrel are briefly described in Table 2 [19].
Table 1: Comparative features of various published case reports with the current case study [7-10]
Parameters Case 1 [7] Case 2 [8] Case 3 [9] Case 4 [10] Case 5 (present)
Age (years) 39 27 24 32 38
Gender Male Male Male Female Male
Past history Hypothyroidism None None Gestational diabetes mellitus 
and amenorrhea since 6 
months
Jaundice 3 years back. 
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11.2 g/dL, Elevated 
RBC indices
11.2 g/dL, Elevated 
RBC indices 
10 g/dL, Elevated 
RBC indices
11g/dL 15.1g/dL Borderline 
high RBC indices
Serum vitamin B12 Very low 
(not mentioned)
158 pg/ml Folate: 
12.1 ng/ml (>3)
48 pg/ml Low 
(value not mentioned)
89 pg/ml
Serum HCY 105 µmol/L 105 µmol/L 16 µmol/L 28.48 µmol/L 15.65 µmol/L
Treatment A (325 mg), 











A+C + inj. E. FA+vit. B12 and 
iron supplements
Strep. + A+antiplatelet 
agents+Ator. + 
M+Nico. + E (tab) vit. 
B12+FA+vit. B6 orally
SC: Subcutaneous, IM: Intramuscular, Inj: Injection, Tab.: Tablet, pg/ml: Picogram per milliliter, g/dl: Gram/deciliter, µmol/L: Micromoles per liter, A: Aspirin, 
Ator.: Atorvastatin, C: Clopidogrel, E: Enoxaparin, Epti.: Eptifibatide, Ep.: Eplerenone, FA: Folic acid, L: Lisinopril, LMWH: Low molecular weight heparin, M: Metoprolol, 
Nico. : Nicorandil, Strep.: Streptokinase, UFH: Unfractionated Heparin, Vit. B12: Vitamin B12, Vit. B6: Vitamin B6, W: Warfarin, RBC: Red blood cell
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CONCLUSION
Mild elevation of HCY levels caused by severe vitamin B12 deficiency 
was managed by oral vitamin B complex supplementation. Vitamin B12 
deficiency and HCY level evaluation can be considered in young patients 
having AMI without any traditional risk factors. In our case, the patient 
was having a family history of ischemic heart disease and followed 
the Mediterranean diet which could be considered as a risk factor 
for coronary artery disease and vitamin B12 deficiency, respectively. 
Hence, in such young patients, it is necessary to check the vitamin B12 
and HCY levels at regular intervals to avoid vascular complications.
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Loading dose 180 mg 300-600 mg
Peak effect 
(after loading dose)
2 hrs 6 hrs
Half life 9 hrs 0.5 hr










More effective, reduced 
rate of death from 
vascular causes or 
myocardial infarction 
or stroke without 
significant increased 
risk of bleeding
Not as effective as 
Ticagrelor + Aspirin 
combination, 
higher rate of 
death from 
vascular causes 
or myocardial 
infarction or stroke
